ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended				9 Months Ended		3 Months Ended	9 Months Ended			3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013 Onglyza Kombiglyze [Member]	Sep. 30, 2012 Onglyza Kombiglyze [Member]	Sep. 30, 2013 Onglyza Kombiglyze [Member]	Sep. 30, 2012 Onglyza Kombiglyze [Member]	Sep. 30, 2013 Forxiga [Member]	Sep. 30, 2013 Forxiga [Member]	Sep. 30, 2013 Bydureon [Member]	Sep. 30, 2012 Bydureon [Member]	Sep. 30, 2013 Bydureon [Member]	Sep. 30, 2012 Bydureon [Member]	Sep. 30, 2013 Byetta [Member]	Sep. 30, 2012 Byetta [Member]	Sep. 30, 2013 Byetta [Member]	Sep. 30, 2012 Byetta [Member]	Sep. 30, 2013 AstraZeneca [Member]	Sep. 30, 2012 AstraZeneca [Member]	Sep. 30, 2013 AstraZeneca [Member]	Sep. 30, 2012 AstraZeneca [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Sep. 30, 2013 AstraZeneca [Member] Forxiga [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Forxiga [Member] Upfront, milestone and other licensing payments [Member]	Sep. 30, 2012 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Sep. 30, 2012 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Sep. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Sep. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Sep. 30, 2012 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Sep. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Sep. 30, 2012 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Sep. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Sep. 30, 2012 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Sep. 30, 2013 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Sep. 30, 2012 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Sep. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Sep. 30, 2012 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Sep. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Sep. 30, 2012 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Sep. 30, 2013 AstraZeneca [Member] Bydureon [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Byetta [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Symlin [Member] Amylin Acquisition [Member]	Sep. 30, 2013 AstraZeneca [Member] Metreleptin [Member] Amylin Acquisition [Member]
Alliances and Collaborations Statement [Line Items]
Number of agreements in collaboration																				3		3
Payment made by a collaboration partner to enter into a collaboration agreement																								$ 3,600,000,000
Portion of preliminary proceeds included in accrued expenses related to collaboration proceeds adjustments																									73,000,000
Useful life - Intangible asset																																															13 years 0 months 0 days	7 years 0 months 0 days	9 years 0 months 0 days	12 years 0 months 0 days
Useful life - Property, plant and equipment																																						15 years 0 months 0 days
Payment to be made by a collaboration partner to establish equal governance rights in the collaboration																									135,000,000
The percentage of capital expenditures to be reimbursed by AstraZeneca																									50.00%
Total upfront, milestone and other licensing payments received																										300,000,000		250,000,000
Potential additional development and regulatory milestone receipts																												150,000,000
Potential additional sales based milestone receipts																										300,000,000		390,000,000
Net Sales	4,065,000,000	3,736,000,000	11,944,000,000	13,430,000,000		211,000,000	178,000,000	653,000,000	511,000,000	7,000,000	15,000,000	87,000,000	20,000,000	205,000,000	20,000,000	106,000,000	55,000,000	295,000,000	55,000,000																								430,000,000	266,000,000	1,219,000,000	599,000,000
Profit sharing - Cost of products sold																				170,000,000	118,000,000	494,000,000	268,000,000
Cost reimbursements to/(from) collaboration partners - Commercialization expenses																				(53,000,000)	(43,000,000)	(172,000,000)	(62,000,000)
Cost reimbursements to/(from) collaboration partner - Research and development																				(17,000,000)	(17,000,000)	(56,000,000)	(7,000,000)
Cost of products sold	1,175,000,000	987,000,000	3,346,000,000	3,535,000,000																														(78,000,000)	(50,000,000)	(227,000,000)	(50,000,000)
Other (income)/expense	5,000,000	(11,000,000)	185,000,000	(246,000,000)																																			(8,000,000)	(9,000,000)	(23,000,000)	(30,000,000)
Upfront, milestone and other licensing payments received																												80,000,000		3,570,000,000	3,570,000,000
Deferred income	$ 5,201,000,000		$ 5,201,000,000		$ 4,849,000,000																			$ 3,500,000,000		$ 195,000,000	$ 208,000,000	$ 196,000,000	$ 206,000,000			$ 3,342,000,000	$ 3,423,000,000